HollandBIO welcomes MeiraGTx as a new member

HollandBIO connects, represents and supports the Dutch life science sector. We are very proud that we already represent over 260 companies: from start-ups, small and medium-sized companies to large companies, active in health, food or biobased economy. Today we welcome MeiraGTx Netherlands, an Amsterdam based biopharmaceutical company developing local gene therapy for different indications. The company specializes in the development of viral gene therapy vectors, in particular adeno-associated virus (AAV) based therapeutics.

“Our mission is to develop potentially curative treatments for patients living with serious diseases. Several product candidates are in the discovery and development phase. In 2021 we have moved to our brand new facility at Paalbergweg 2 in Amsterdam, with tailor made laboratories to execute our R&D and vector production activities. Meira GTx Netherlands B.V. is a wholly-owned subsidiary of MeiraGTx Holdings plc. With sites in New York, London, Shannon, and Amsterdam, our global footprint provides us the opportunity to partner with leading institutions around the world, allowing us to deepen our understanding of diseases and their progression.”